Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;36(1):51-57.
doi: 10.1007/s00345-017-2093-6. Epub 2017 Oct 11.

Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy

Marco Bandini  1   2   3 , Ariane Smith  4 , Emanuele Zaffuto  5   6   4 , Raisa S Pompe  4   7 , Michele Marchioni  4   8 , Umberto Capitanio  5   6 , Felix K Chun  7 , Anil B Kapoor  9 , Shahrokh F Shariat  10 , Francesco Montorsi  5   6 , Alberto Briganti  5   6 , Pierre I Karakiewicz  4
Affiliations

Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy

Marco Bandini et al. World J Urol. 2018 Jan.

Abstract

Purpose: Adjuvant therapies for non-metastatic renal cell carcinoma (nmRCC) are being tested to improve outcomes in patients with high-risk (hR) nmRCC. The objective of the current study is to test the ability of three hR features to identify patients who are at the highest risk of cancer-specific mortality (CSM) after partial or radical nephrectomy.

Methods: Within the Surveillance Epidemiology and End Results (SEER) database (1988-2013), we identified 23,632 nm "clear cell" RCC partial or radical nephrectomy patients with hR features: Fuhrman grade (FG) 3 or 4 or pathological classifications T3a or T3b or lymph node invasion (LNI), or combination of these. Kaplan-Meier analyses (KM) and multivariable Cox's regression models (CRM) evaluated the effect of hR features on CSM.

Results: Overall 11,568 (48.9%) patients harbored FG3-4, 5575 (23.6%) pT3a/b, 140 (0.6%) LNI, 5366 (22.7%) FG3-4 and pT3a/b, 183 (0.8%) LNI and pT3a/b, 203 (0.9%) LNI and FG3-4 and 597 (2.5%) LNI, FG3-4 and pT3a/b. Median CSM-free survival was 51, 58 and 22 months for LNI and pT3a/b, for LNI and FG3-4 and for LNI, FG3-4 and pT3a/b and was not reached for the other groups. These results remained unchanged in multivariable CRMs, where all hR features represented independent predictors.

Conclusions: Individuals with combination of LNI with FG3-4 or pT3a/b and patients with all three hR features are at highest risk of CSM. In consequence, these patients may represent ideal candidates for adjuvant therapy either in clinical practice or future prospective trials.

Keywords: Adjuvant therapy; Clear cell; Kidney cancer; Non-metastatic renal cell carcinoma; Targeted molecular therapy.

PubMed Disclaimer

References

    1. BJU Int. 2009 Jan;103(1):33-7 - PubMed
    1. Biometrics. 1982 Dec;38(4):921-32 - PubMed
    1. N Engl J Med. 2016 Dec 8;375(23 ):2246-2254 - PubMed
    1. J Clin Oncol. 2017 Dec 10;35(35):3916-3923 - PubMed
    1. Lancet. 2016 May 14;387(10032):2008-16 - PubMed

Supplementary concepts